If you've wondered why your GLP-1 starts at a dose that barely does anything, that's by design. Titration, the stepwise climb to your target dose, exists mostly to keep side effects manageable. Once you see the logic, the first few months of treatment make more sense.
Why doses start low and climb gradually
Every approved GLP-1 medication uses a titration schedule: it starts well below the eventual target dose and increases in steps, usually every few weeks. The low starting doses are generally below the level needed for meaningful blood sugar or weight effects. Their job is tolerability. They give your digestive system time to adjust to slower stomach emptying before the dose goes up, and the labels set out the step-up schedule specifically to reduce the risk of stomach side effects.
The general pattern across GLP-1 medications
Schedules vary by drug but share a shape. A low starting dose is held for a set period (commonly about 4 weeks, though some drugs step up weekly), then the dose rises at set intervals until you reach a target maintenance dose or the highest dose you tolerate. The exact doses, step sizes and timing differ between drugs, so follow your own prescribed schedule and check details with your prescriber or pharmacist instead of assuming another drug's schedule applies to yours.
Why the schedule matters for side effects
Our guide on the GLP-1 side effect timeline covers how side effects bunch up around each dose increase. That pattern follows from the titration structure, and it's well documented. In pooled data from the STEP 1–3 trials (2,117 people on semaglutide 2.4 mg and 1,262 on placebo), stomach and gut side effects happened most often during or shortly after dose escalation. They were almost all non-serious (99.5%) and mild to moderate (98.1%), and only 4.3% of participants stopped treatment permanently because of them (Wharton et al., Diabetes, Obesity & Metabolism, 2021, DOI (external link)). That's the case for stepping up slowly: the difficulty is concentrated at the transitions, and it passes.
Side effects that spike after an increase and then ease before the next step are expected. Moving faster than the schedule, including restarting at your old dose after a gap instead of re-titrating, can bring on more severe symptoms, and in serious cases dehydration and kidney injury.
Restarting after a break: why you re-titrate
This is the part of titration people most often get wrong. You build tolerance to the stomach effects during the climb, and it fades when you stop the medication. Going straight back to your old dose after a long gap can bring back the side effects that slow titration was meant to prevent. The FDA labels build this in. Wegovy's prescribing information says that if two or more consecutive doses of the injection are missed, dose escalation should restart at a lower dose to reduce the risk of stomach side effects. Saxenda's label says to restart at the 0.6 mg starting dose and re-titrate if more than three days have been missed (FDA labels via DailyMed, rev. 2026). One case report describes a patient who resumed semaglutide at a high prior dose without re-titrating and developed severe stomach symptoms, dehydration and acute kidney injury (Singhal et al., Cureus, 2025, DOI (external link)). A single case shows what can happen, not how often it does.
Missing a dose or two is a different situation, handled by the standard missed-dose rules. Re-titration matters after longer gaps, and the cutoff varies by drug. Our guide on stopping and restarting a GLP-1 covers longer breaks in more detail.
If titration feels too fast for you
If side effects haven't settled by the time your next increase is due, it's reasonable to ask your prescriber about staying at your current step longer. The standard schedule is a typical pace, and a slower climb is a normal adjustment. Wegovy's label says to consider delaying a dose increase for 4 weeks if a dose isn't tolerated, and it lists 1.7 mg as an approved maintenance dose alongside 2.4 mg, so staying lower is also within the label. See our guide on why some people stay on a lower maintenance dose for more.
Study findings above are attributed to their authors and were located via PubMed.
This article is for general education and is not medical advice. Your titration pace and any changes to it belong in a conversation with your prescriber.